Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 16th August 2019
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Stem cell treatment a ‘breakthrough’ for equine lameness
“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage".
Arti-Cell Forte is the first stem cell-based medicine to receive marketing authorisation

The first stem cell-based medicine to receive marketing authorisation for the treatment of equine lameness has been launched by Boehringer Ingelheim.

Hailed as a ‘breakthrough medicine’ for degenerative joint disease in horses, Arti-Cell Forte is the first ‘ready-to-use’ stem cell-based product to be licensed in any veterinary species. It is also the only stem cell treatment to contain induced cells, marking a significant step in stem cell therapies and medicine as a whole.

“Arti-Cell® Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage,” explained DR Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager.

“Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses. This makes Arti-Cell® Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease.”

The medicine is available to veterinary practitioners direct from Boehringer Ingelheim. It is stored at ultra-low temperatures to maintain its two-year shelf life, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately before injecting. 

Full training on storage and administration of the medicine is available from the Boehringer via face-to-face CPD at practice meetings or specific CPD events. For more information about these events, email vetenquiries@boehringer-ingelheim.com 

Become a member or log in to add this story to your CPD history

BEVA gives RVNs right to vote

News Story 1
 The British Equine Veterinary Association (BEVA) is to allow its registered veterinary nurse (RVN) members the right to vote.

RVN members will now be able to take part in key decision-making processes and stand for BEVA council.

Marie Rippingale, chair of BEVA's Nurse Committee, said: "I am very proud to be a part of BEVA.

"This change will help to empower nurses to speak up and contribute, but more importantly, it will give them an opportunity to collaborate with other members of the equine veterinary profession to bring about change that is positive for all." 

Click here for more...
News Shorts
Northern Ireland chief vet warns of bluetongue risk

Following the detection of bluetongue virus serotype 3 (BTV-3) in England, Northern Ireland's chief veterinary officer has urged farmers to remain vigilant and source animals responsibly.

Brian Dooher said: "This confirmation in England is a stark reminder of the threat bluetongue presents to Northern Ireland.Whilst this finding in Norfolk is disappointing it is not unexpected giving the rising level of disease across several countries in Europe. Bluetongue does not affect human health or food safety, however an incursion to Northern Ireland would have a significant impact on livestock and the rural economy.

"I would like to remind all farmers of the importance of sourcing animals responsibly and ask that they maintain vigilance for signs of the disease reporting any suspicions to DAERA immediately."

Suspected cases of BTV-3 in Northern Ireland should be reported to the DAERA Helpline on 0300 200 7840 or by contacting the local DAERA Direct Veterinary Office.